Clinical Microbiology Reviews· 2019Q1
Echinococcosis: Advances in the 21st Century
- 1,206citations
- Q1SCImago
- 2019year
Short summary
Genomic and proteomic data are emerging as key platforms for developing new drugs and vaccines against echinococcosis, a persistent global challenge.
AI-generated from the title and abstract; the full text is not read.
Key points
- Surgical techniques like autotransplantation and percutaneous procedures have enhanced echinococcosis treatment.
- Albendazole is currently the only available drug for echinococcosis, highlighting an urgent need for alternatives.
- Genomic and proteomic research provides a basis for developing new diagnostic methods, drugs, and vaccines.
- Echinococcosis remains a significant global health challenge requiring continued control efforts.
AI-generated from the title and abstract; the full text is not read.
Abstract
resection with autotransplantation in AE, and percutaneous and perendoscopic procedures in both diseases have improved treatment efficacy and the quality of life of patients. In this review, we summarize recent progress on the biology, epidemiology, diagnosis, management, control, and prevention of CE and AE. Currently there is no alternative drug to albendazole to treat echinococcosis, and new compounds are required urgently. Recently acquired genomic and proteomic information can provide a platform for improving diagnosis and for finding new drug and vaccine targets, with direct impact in the future on the control of echinococcosis, which continues to be a global challenge.
The authors' abstract, as published at the source. Clinical Microbiology Reviews, 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine